keyword
MENU ▼
Read by QxMD icon Read
search

Fallopian tube cancer

keyword
https://www.readbyqxmd.com/read/29782365/utilization-of-an-alternative-docetaxel-based-intraperitoneal-chemotherapy-regimen-in-patients-with-ovarian-fallopian-tube-or-primary-peritoneal-carcinoma-a-continued-need-for-ovarian-cancer-patients
#1
David A Becker, Charles A Leath, Christen L Walters-Haygood, Brentley Q Smith, Kerri S Bevis
OBJECTIVE: The objective of this study was to report the tolerability and toxicity of a regimen consisting of intravenous (IV) docetaxel and intraperitoneal (IP) cisplatin and paclitaxel with granulocyte colony-stimulating factor support. MATERIALS AND METHODS: We conducted a retrospective cohort study of patients with surgical stage II-IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma treated with an outpatient IP chemotherapy regimen consisting of docetaxel 75 mg/m IV and cisplatin 75 mg/m IP day 1 followed by paclitaxel 60 mg/m IP day 8 every 21 days...
May 18, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29773902/nedd9-promotes-oncogenic-signaling-a-stem-mesenchymal-gene-signature-and-aggressive-ovarian-cancer-growth-in-mice
#2
Rashid Gabbasov, Fang Xiao, Caitlin G Howe, Laura E Bickel, Shane W O'Brien, Daniel Benrubi, Thuy-Vy Do, Yan Zhou, Emmanuelle Nicolas, Kathy Q Cai, Samuel Litwin, Sachiko Seo, Erica A Golemis, Denise C Connolly
Neural precursor cell expressed, developmentally downregulated 9 (NEDD9) supports oncogenic signaling in a number of solid and hematologic tumors. Little is known about the role of NEDD9 in ovarian carcinoma (OC), but available data suggest elevated mRNA and protein expression in advanced stage high-grade cancers. We used a transgenic MISIIR-TAg mouse OC model combined with genetic ablation of Nedd9 to investigate its action in the development and progression of OC. A Nedd9-/- genotype delayed tumor growth rate, reduced incidence of ascites, and reduced expression and activation of signaling proteins including SRC, STAT3, E-cadherin, and AURKA...
May 18, 2018: Oncogene
https://www.readbyqxmd.com/read/29770616/prevalence-of-germline-brca-mutations-among-women-with-carcinoma-of-the-peritoneum-or-fallopian-tube
#3
Min Chul Choi, Jin Sik Bae, Sang Geun Jung, Hyun Park, Won Duk Joo, Seung Hun Song, Chan Lee, Ji Ho Kim, Ki Chan Lee, Sunghoon Lee, Je Ho Lee
OBJECTIVE: The aim of the present study was to assess the frequency of germline mutations in patients with peritoneal carcinoma (PC) or the fallopian tube carcinoma (FTC), using a multi-gene panel. METHODS: Twenty-six patients diagnosed with either PC or FTC between January 2013 and December 2016 were recruited consecutively. Germline DNA was sequenced using a 6-gene next generation sequencing (NGS) panel following genetic counseling. Surgico-medical information was obtained from hospital records...
March 26, 2018: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29767688/safety-and-dose-modification-for-patients-receiving-niraparib
#4
J S Berek, U A Matulonis, U Peen, P Ghatage, S Mahner, A Redondo, A Lesoin, N Colombo, I Vergote, O Rosengarten, J Ledermann, M Pineda, S Ellard, J Sehouli, A Gonzalez-Martin, D Berton-Rigaud, R Madry, A Reinthaller, S Hazard, W Guo, M R Mirza
Background: Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved in the United States and Europe for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. In the pivotal ENGOT-OV16/NOVA trial, the dose reduction rate due to TEAE was 68.9%, and the discontinuation rate due to TEAE was 14.7%, including 3.3% due to thrombocytopenia. A retrospective analysis was performed to identify clinical parameters that predict dose reductions...
May 14, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29754740/detection-of-endometrial-cancer-cells-in-the-fallopian-tube-lumen-is-associated-with-adverse-prognostic-factors-and-reduced-survival
#5
Ashley S Felix, Jennifer A Sinnott, Monica Hagan Vetter, Jennifer Rhoades, David E Cohn, Floor J Backes, Mark E Sherman, Adrian A Suarez
OBJECTIVE: Stage is a critical determinant of prognosis and treatment for endometrial cancer (EC) patients. Women who have had a tubal ligation for sterilization have improved EC survival, secondary to lower stage at presentation, suggesting that transtubal spread may represent an important route of metastasis. We evaluated detection of intraluminal tumor cells (ILTCs) in relation to tumor characteristics and survival. METHODS: One pathologist retrospectively evaluated hematoxylin and eosin sections of routinely collected fallopian tubes for ILTCs from 295 EC patients, masked to outcome...
May 10, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29752319/misdiagnosis-of-li-fraumeni-syndrome-in-a-patient-with-clonal-hematopoiesis-and-a-somatic-tp53-mutation
#6
Rachel L Mitchell, Cory Kosche, Kelly Burgess, Shreya Wadhwa, Lela Buckingham, Ritu Ghai, Jacob Rotmensch, Oleksandra Klapko, Lydia Usha
Li-Fraumeni syndrome (LFS) is a rare genetic disorder that confers a high risk of developing certain malignancies at a young age. It is caused by germline mutations in the TP53 gene and is typically diagnosed by sequencing this gene in blood cells. The presence of a mutation in approximately half of the DNA reads (allelic fraction of 50%) is an indicator of a germline mutation, such as that in LFS. Clonal hematopoiesis (CH) is an expansion of a hematopoietic clone containing a somatic driver mutation with a low allelic fraction, usually not more than 10% to 20%...
May 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29739622/phase-ii-study-of-single-agent-cabozantinib-in-patients-with-recurrent-clear-cell-ovarian-primary-peritoneal-or-fallopian-tube-cancer-nrg-gy001
#7
Panagiotis A Konstantinopoulos, William E Brady, John Farley, Amy Armstrong, Denise S Uyar, David M Gershenson
OBJECTIVE: To evaluate the efficacy and tolerability of cabozantinib in recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer. METHODS: Patients with recurrent ovarian, fallopian or primary peritoneal tumors with at least 50% clear cell histomorphology, measurable disease, one or two prior regimens and ECOG performance status 0-2 received cabozantinib 60 mg orally once daily continuously, in 4-week cycles until disease progression or unacceptable toxicity...
May 5, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29737528/preterm-delivery-is-associated-with-an-increased-risk-of-epithelial-ovarian-cancer-among-parous-women
#8
Camilla Sköld, Tone Bjørge, Anders Ekbom, Anders Engeland, Mika Gissler, Tom Grotmol, Laura Madanat, Anne Gulbech Ording, Olof Stephansson, Britton Trabert, Steinar Tretli, Rebecca Troisi, Henrik Toft Sørensen, Ingrid Glimelius
Epithelial ovarian cancer is a fatal disease of largely unknown etiology. Higher parity is associated with reduced risk of ovarian cancer. However, among parous women, the impact of pregnancy-related factors on risk is not well understood. This population-based case-control study included all parous women with epithelial ovarian cancer in Denmark, Finland, Norway and Sweden during 1967-2013 (n=10,957) and up to 10 matched controls (n=107,864). We used conditional logistic regression to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for pregnancy-related factors and ovarian cancer risk by histological subtype...
May 8, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29731902/identification-of-candidate-genes-associated-with-tubal-origin-of-high-grade-serous-ovarian-cancer
#9
Li Xiang, Guohua Rong, Jing Zhao, Zhenyan Wang, Fengfeng Shi
Evidence indicates that high-grade serous ovarian carcinoma arises from the fallopian tube, rather than ovarian surface epithelium. This is termed the 'tubal origin' theory. The aim of the present study was to compare the immunophenotype and gene expression profiling among high-grade serous ovarian carcinoma (HGSOC), fallopian tube epithelium (FTE) and ovarian surface epithelium (OSE) based on tubal origin theory, and identify the differential genes associated with ovarian carcinogenesis. A total of 61 cases of fresh tissue samples including 21 cases of HGSOC, 20 cases of OSE, and 20 cases of FTE were obtained following surgical resection...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29730436/a-rare-finding-at-colonoscopy-metastatic-fallopian-tube-cancer
#10
Dominique Kasindi, Matthew Lewin, Rajeev Jain
No abstract text is available yet for this article.
May 3, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29707124/-brca1-2-and-tp53-mutation-status-associates-with-pd-1-and-pd-l1-expression-in-ovarian-cancer
#11
Verena Wieser, Inge Gaugg, Martina Fleischer, Giridhar Shivalingaiah, Soeren Wenzel, Susanne Sprung, Sigurd F Lax, Alain G Zeimet, Heidelinde Fiegl, Christian Marth
Checkpoint molecules such as programmed cell death protein-1 (PD-1) and its ligand PD-L1 are critically required for tumor immune escape. The objective of this study was to investigate tumoral PD-1 and PD-L1 mRNA-expression in a cohort of ovarian cancer (OC) patients in relation to tumor mutations. We analyzed mRNA expression of PD-1 , PD-L1 and IFNG by quantitative real-time PCR in tissue of 170 patients with low grade-serous (LGSOC), high-grade serous (HGSOC), endometrioid and clear cell OC compared to 28 non-diseased tissues (ovaries and fallopian tubes) in relation to tumor protein 53 ( TP53 ) and breast cancer gene 1/2 ( BRCA1/2 ) mutation status...
April 3, 2018: Oncotarget
https://www.readbyqxmd.com/read/29703236/high-grade-serous-carcinoma-with-discordant-p53-signature-report-of-a-case-with-new-insight-regarding-high-grade-serous-carcinogenesis
#12
Yuichiro Hatano, Shinya Fukuda, Hiroshi Makino, Hiroyuki Tomita, Ken-Ichirou Morishige, Akira Hara
BACKGROUND: Although p53 signature, benign-appearing epithelial cells with p53 diffuse expression, is frequently found in the fallopian tubes, the clinical and pathological significance of this lesion in the case of high-grade serous carcinoma (HGSC) patients still remains unclear. CASE PRESENTATION: A 56-year-old woman was referred to the gynecologist on account of abdominal distention. Since radiological and serological workup suggested that her illness was due to advanced ovarian cancer (FIGO Stage IVB), she received neoadjuvant chemotherapy, and the clinical evaluation of the chemotherapeutic response was a partial response...
April 27, 2018: Diagnostic Pathology
https://www.readbyqxmd.com/read/29676714/-does-ovarian-cancer-start-in-the-fallopian-tubes-possible-implications-for-preventive-adnexal-removal
#13
M P Steenbeek, J Bulten, N Hoogerbrugge, L F A G Massuger, J M A Pijnenborg, J A de Hullu
BACKGROUND: Recent insights in high-grade serous ovarian cancer development are pointing to the fallopian tubes as likely place of origin and not the ovaries themselves. This may have consequences for patients with increased risk of ovarian cancer. Adnexal removal is currently recommended for this patient group at an age of 35-45, which leads to premature menopause. CASE DESCRIPTION: In a 55-year-old woman with a BRCA1 germ line mutation, a high-grade serous carcinoma was unexpectedly diagnosed in both fallopian tubes during preventive adnexal removal...
2018: Nederlands Tijdschrift Voor Geneeskunde
https://www.readbyqxmd.com/read/29675469/noninvasive-ovarian-cancer-biomarker-detection-via-an-optical-nanosensor-implant
#14
Ryan M Williams, Christopher Lee, Thomas V Galassi, Jackson D Harvey, Rachel Leicher, Maria Sirenko, Madeline A Dorso, Janki Shah, Narciso Olvera, Fanny Dao, Douglas A Levine, Daniel A Heller
Patients with high-grade serous ovarian carcinoma (HGSC) exhibit poor 5-year survival rates, which may be significantly improved by early-stage detection. The U.S. Food and Drug Administration-approved biomarkers for HGSC-CA-125 (cancer antigen 125) and HE4 (human epididymis protein 4)-do not generally appear at detectable levels in the serum until advanced stages of the disease. An implantable device placed proximal to disease sites, such as in or near the fallopian tube, ovary, uterine cavity, or peritoneal cavity, may constitute a feasible strategy to improve detection of HGSC...
April 2018: Science Advances
https://www.readbyqxmd.com/read/29670794/coexistence-of-cervical-leiomyosarcoma-and-gastric-type-adenocarcinoma-in-situ-with-extensive-extension-to-the-endometrium-and-fallopian-tube
#15
Ayako Ura, Kanako Ogura, Asumi Sakaguchi, Hiroko Onagi, Daiki Ogishima, Yayoi Sugimori, Kensuke Hamamura, Masaharu Fukunaga, Toshiharu Matsumoto
Cervical leiomyosarcoma is known to be rare from the previous reviews of a large number of malignant cervical tumors. The patient was a 66-year-old woman with irregular vaginal bleeding. She underwent modified radical hysterectomy and bilateral salpingooophorectomy. Histopathologically, we diagnosed the coexistence of uterine cervical leiomyosarcoma and cervical gastric-type adenocarcinoma in situ with endometrial lesions that had continuous and skip patterns and fallopian tubal lesions with a partial lesion...
2018: Case Reports in Pathology
https://www.readbyqxmd.com/read/29650751/fda-approval-summary-niraparib-for-the-maintenance-treatment-of-patients-with-recurrent-ovarian-cancer-in-response-to-platinum-based-chemotherapy
#16
Gwynn Ison, Lynn J Howie, Laleh Amiri-Kordestani, Lijun Zhang, Shenghui Tang, Rajeshwari Sridhara, Vadryn Pierre, Rosane Charlab, Anuradha Ramamoorthy, Pengfei Song, Fang Li, Jingyu Yu, Wimolnut Manheng, Todd R Palmby, Soma Ghosh, Hisani N Horne, Eunice Y Lee, Reena Philip, Kaushalkumar Dave, Xiao Hong Chen, Sharon L Kelly, Kumar G Janoria, Anamitro Banerjee, Okponanabofa Eradiri, Jeannette Dinin, Kirsten B Goldberg, William F Pierce, Amna Ibrahim, Paul G Kluetz, Gideon M Blumenthal, Julia A Beaver, Richard Pazdur
The Food and Drug Administration approved niraparib, a poly ADP ribose polymerase (PARP) inhibitor, on March 27, 2017, for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy. Approval was based on data from the NOVA trial comparing niraparib with placebo in two independent cohorts, based on germline BRCA mutation status (gBRCAm vs. non-gBRCAm). Progression-free survival (PFS) in each cohort was the primary endpoint...
April 12, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29648645/does-human-endometrial-lgr5-gene-expression-suggest-the-existence-of-another-hormonally-regulated-epithelial-stem-cell-niche
#17
N Tempest, A M Baker, N A Wright, D K Hapangama
STUDY QUESTION: Is human endometrial leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) gene expression limited to the postulated epithelial stem cell niche, stratum basalis glands, and is it hormonally regulated? SUMMARY ANSWER: LGR5 expressing cells are not limited to the postulated stem cell niche but LGR5 expression is hormonally regulated. WHAT IS KNOWN ALREADY: The human endometrium is a highly regenerative tissue; however, endometrial epithelial stem cell markers are yet to be confirmed...
April 10, 2018: Human Reproduction
https://www.readbyqxmd.com/read/29629944/human-endometriosis-tissue-microarray-reveals-site-specific-expression-of-estrogen-receptors-progesterone-receptor-and-ki67
#18
Mariano Colón-Caraballo, Miosotis García, Adalberto Mendoza, Idhaliz Flores
Most available therapies for endometriosis are hormone-based and generally broadly used without taking into consideration the ovarian hormone receptor expression status. This contrasts strikingly with the standard of care for other hormone-based conditions such as breast cancer. We therefore aimed to characterize the expression of ovarian steroid hormone receptors for estrogen alpha (ESR1), estrogen beta (ESR2), and progesterone (PGR) in different types of endometriotic lesions and eutopic endometrium from women with endometriosis and controls using a tissue microarray (TMA)...
April 7, 2018: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/29624506/laparoscopic-assessment-to-determine-the-likelihood-of-achieving-optimal-cytoreduction-in-patients-undergoing-primary-debulking-surgery-for-ovarian-fallopian-tube-or-primary-peritoneal-cancer
#19
Vaagn Andikyan, Annie Kim, Herbert F Gretz, Konstantin Zakashansky, Monica Prasad-Hayes, Ann-Marie Beddoe, Peter Dottino, John Mandeli, Linus Chuang
OBJECTIVE: The objective of this study was to evaluate the safety and efficacy of laparoscopic assessment to determine the likelihood of achieving optimal cytoreduction (OC) in patients undergoing primary debulking surgery (PDS) for ovarian cancer. METHODS: All patients who underwent diagnostic laparoscopy and PDS at our institution from January 2008 to December 2013 were identified. We determined the likelihood of achieving optimal cytoreduction by laparoscopic assessment based on tumor site, pattern of spread, and disease burden...
April 5, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29623583/pathology-findings-and-clinical-outcomes-after-risk-reduction-salpingo-oophorectomy-in-brca-mutation-carriers-a-multicenter-spanish-study
#20
L Minig, S Cabrera, R Oliver, A Couso, M J Rubio, S Iacoponi, M B Martin-Salamanca, S Carballo-Rastrilla, J M Cádenas-Rebollo, A García-Garcia, B Gil-Ibáñez, M J Juan-Fita, M G Patrono
OBJECTIVE: To determine the incidence of serous tubal intraepithelial carcinoma (STIC) after risk reduction salpingo-oophorectomy(RRSO), and to describe oncological outcomes after RRSO. MATERIALS AND METHODS: BRCA pathogenic mutation carriers who had undergone an RRSO were evaluated in this retrospective multicenter observational study. Patients were only included when fallopian tubes were analyzed following the protocol for Sectioning and Extensively Examining the FIMbria (SEE-FIM)...
April 5, 2018: Clinical & Translational Oncology
keyword
keyword
43221
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"